Schwarzman's Blackstone buys Japanese drugs subsidiary
Deal announced Monday is valued at $2.3 billion
TOKYO (AP) — Takeda Pharmaceutical Co. is selling its subsidiary in Japan focused on consumer healthcare to U.S. investment fund Blackstone Group.
The deal, announced Monday by the Japanese drugs manufacturer, is valued at 242 billion yen ($2.3 billion), although the exact sales price will be determined later, after adjustments for debt and capital of the subsidiary, Takeda Consumer Healthcare Co.
BLACKSTONE'S STEPHEN SCHWARZMAN PRACTICES PHILANTHROPY FOR THE LONG HAUL
The deal will likely be completed by March 2021, according to Tokyo-based Takeda.
Takeda said it wants to focus on specialized areas, such as disorders of the digestive system, rare diseases, plasma-derived therapies and the prevention and treatment of cancer, rather than the increasingly competitive consumer sector.
Stephen Schwarzman, co-founder and chief executive officer of Blackstone Group Inc., stands for a photograph before an interview in New York, Sept. 13, 2019. Photographer: David 'Dee' Delgado/Bloomberg via Getty Images
The subsidiary, spun off in 2017, sells drugs popular in Japan called Alinamin, a type of vitamin supplement, and Bendex, a cold remedy.
Blackstone plans to develop the business and retain all the workers, Takeda's statement said.
CLICK HERE TO READ MORE ON FOX BUSINESS
Takeda, among the global companies working on a treatment for COVID-19, expects the sale to boost its net profit by about 105 billion yen ($1 billion).
Takeda, which acquired international biotech company Shire in 2019, has recently been selling off what it sees as its other non-core assets, including manufacturing sites in Europe and products in South America.